Addyi Cost in Virginia 2026: Price, Insurance, Medicaid, and Compounding Options

What Is Flibanserin and Why Does It Carry a High Price Tag?

Flibanserin, sold as Addyi, is the first FDA-approved pharmacological treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA granted approval on August 18, 2015, after Sprout Pharmaceuticals completed the BEGONIA and VIOLET trials. Brand-name specialty drugs with no generic equivalent routinely carry list prices above $800 per month, and Addyi is no exception. Sprout holds orphan-adjacent market exclusivity, which limits price competition from other branded products.

The drug works primarily as a serotonin 1A agonist and serotonin 2A antagonist, acting on central pathways that modulate sexual desire rather than peripheral vasculature. That central mechanism required a Risk Evaluation and Mitigation Strategy (REMS) program at launch because of the alcohol interaction risk, though FDA updated the REMS in 2019 to remove the pharmacy-level certification requirement, making dispensing more accessible. The updated prescriber REMS is still active [1].

HSDD affects an estimated 8 to 10 percent of premenopausal women in the United States, based on data from the Women's International Study of Health and Sexuality [2]. Virginia has roughly 2.1 million premenopausal women aged 18 to 51 (U.S. Census Bureau 2023 estimate), meaning tens of thousands of Virginia residents may be clinically eligible for treatment.

The 2026 Brand Price of Addyi in Virginia

The Sprout Pharmaceuticals manufacturer list price for Addyi in 2026 is $880 per month for a supply of 30 tablets (100 mg each). Cash-pay retail prices across Virginia pharmacies track closely to this figure. GoodRx and similar coupon aggregators may show discounted cash prices, but confirmed Virginia retail pharmacy pricing for 2026 aligns with the $880 list price in the absence of insurance or manufacturer assistance.

That $880 figure reflects the wholesale acquisition cost before pharmacy markup. Patients paying out of pocket without any discount program face the full retail price, which may exceed $900 at some Virginia chains once dispensing fees are added.

Contrast this with the cost of compounded flibanserin. A licensed Virginia 503A compounding pharmacy can prepare patient-specific formulations, and several charge substantially less, sometimes near cost of raw active pharmaceutical ingredient plus compounding labor. Some telehealth platforms that partner with 503A pharmacies list compounded flibanserin as low as $0 to $99 per month for their membership programs, though pricing varies by pharmacy and platform. See the compounding section below for the legal framework governing that option.

For context, the BEGONIA trial published in the Journal of Sexual Medicine (N=1,378) showed that flibanserin 100 mg nightly produced a statistically significant increase in the number of satisfying sexual events (SSEs) versus placebo at 24 weeks (P<0.001), establishing the efficacy that supports the drug's market position [3].

Virginia Medicaid Coverage for Addyi

Virginia Medicaid covers Addyi for premenopausal women with HSDD, but a prior authorization (PA) is required before the claim will be paid. This is the standard coverage pathway for specialty drugs under Virginia's Medicaid program, administered through managed care organizations (MCOs) including Anthem HealthKeepers Plus, Molina Healthcare of Virginia, Optima Health Community Care, and United Healthcare Community Plan.

To obtain PA approval, prescribers typically must document:

1. A confirmed diagnosis of HSDD using DSM-5 criteria.
2. Absence of contributing medical or psychiatric causes that have not been addressed.
3. Patient acknowledgment of the alcohol interaction warning (a REMS requirement).
4. Attestation that the patient is premenopausal.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on Female Sexual Dysfunction states that HSDD is "the most commonly reported female sexual complaint" and notes that pharmacological options including flibanserin should be discussed with eligible patients [4]. Providing this guideline language in the PA submission letter can strengthen the clinical justification.

Virginia Medicaid MCOs typically respond to PA requests within 3 to 5 business days for non-urgent requests. If denied, prescribers and patients have the right to appeal through the MCO's internal process and, if needed, through Virginia's Medicaid Fair Hearing process administered by the Department of Medical Assistance Services (DMAS).

Patients covered under Virginia's Medicaid expansion (which extended eligibility to adults with incomes up to 138 percent of the federal poverty level under the ACA) became eligible for this benefit starting January 1, 2019. Enrollment has grown to over 600,000 Virginians under the expansion [5].

Commercial Insurance Coverage for Addyi in Virginia

Most commercial insurance plans in Virginia cover Addyi, but formulary placement and cost-sharing vary significantly. Plans regulated under the ACA must cover FDA-approved drugs when a prescriber documents medical necessity, but HSDD medications are not in any mandated preventive care category, so cost-sharing applies.

Typical coverage tiers across Virginia commercial plans in 2026:

• Tier 3 (preferred brand): Patient copay $50 to $100 per month after deductible.
• Tier 4 (non-preferred brand): Patient copay $100 to $200 per month after deductible.
• Tier 5 (specialty): Patient pays 20 to 33 percent coinsurance, which at an $880 list price means $176 to $290 out of pocket per month after meeting the deductible.

Employer-sponsored plans administered by Cigna, Aetna, UnitedHealthcare, and Blue Cross Blue Shield of Virginia (Anthem) represent the majority of commercially insured Virginians. Formulary status for Addyi differs by plan year and by the specific plan design an employer selects. Checking the current plan's drug formulary directly, or calling the pharmacy benefits manager (PBM), gives the most accurate cost before prescribing.

BCBS Federal Employee Program (FEP), which covers federal employees including many Northern Virginia and Richmond federal workers, has historically covered Addyi at the brand tier with a fixed copay structure.

The Sprout Pharmaceuticals Savings Card in Virginia

Sprout Pharmaceuticals offers a manufacturer savings card program for commercially insured patients who qualify. Eligible patients with commercial insurance may pay as little as $0 per month for Addyi through this program, with Sprout covering the remaining cost up to a monthly cap.

Key eligibility rules for the savings card:

• Patient must have commercial insurance (Medicare, Medicaid, and other government-funded plans are excluded).
• The prescriber must be enrolled in the Addyi REMS program [1].
• The savings card applies only to brand-name Addyi, not to compounded flibanserin.
• Income-based eligibility limits may apply; patients must review current program terms at the Sprout patient assistance portal.

For uninsured patients or those whose plans explicitly exclude Addyi, Sprout's Patient Assistance Program (PAP) may provide the drug at no cost, subject to income verification. Virginia residents should confirm current income thresholds directly with Sprout, as these can change annually.

The HealthRX clinical team has developed a decision framework for Virginia patients navigating Addyi access. Step one: verify insurance formulary status and tier. Step two: if commercially insured and Addyi is covered, apply the Sprout savings card to reduce copay. Step three: if insured but PA is required, submit with ACOG guideline language and DSM-5 documentation. Step four: if on Virginia Medicaid, submit PA through your MCO. Step five: if uninsured or the brand cost remains prohibitive after all discounts, discuss compounded flibanserin with a licensed 503A Virginia pharmacy through a telehealth or in-person prescriber.

Is Compounded Flibanserin Legal in Virginia?

Compounded flibanserin is available in Virginia through licensed 503A compounding pharmacies, and prescribing it is legal under current federal and state law, provided specific conditions are met. Virginia law aligns with federal standards under the Drug Quality and Security Act (DQSA) of 2013 for 503A facilities.

A 503A compounding pharmacy prepares medications on a patient-specific basis, meaning a licensed prescriber must write an individualized prescription. The pharmacy compounds based on that prescription, which differs from 503B outsourcing facilities that compound in bulk for office use without patient-specific orders. Virginia Board of Pharmacy regulations require 503A pharmacies to comply with USP standards for compounded sterile and non-sterile preparations, and flibanserin compounded as an oral tablet falls under non-sterile guidelines [6].

FDA does not list flibanserin on the Demonstrably Difficult to Compound list, nor on the list of drugs withdrawn from the market for safety reasons, so compounding is not federally prohibited. The agency has, however, noted that compounding copies of commercially available drugs raises regulatory questions under Section 503A(b), which bars compounding of drugs that are "essentially a copy" of a commercially available product unless there is a documented clinical difference for the specific patient [7].

In practice, prescribers in Virginia who write for compounded flibanserin typically document clinical rationale, such as patient inability to afford the branded product after exhausting all assistance programs. A written clinical justification in the prescription and medical record reduces regulatory risk for the prescribing clinician and the compounding pharmacy.

The Virginia Board of Medicine has not issued a separate guidance letter specifically addressing flibanserin compounding as of the last review date. Prescribers should consult the board's current advisory opinions and the DMAS formulary if prescribing for Medicaid patients [8].

Telehealth Prescribing of Addyi in Virginia

Virginia law permits telehealth prescribing of controlled and non-controlled medications including Addyi, which is not a controlled substance. The Virginia Telehealth Initiative and the 2020 amendments to the Virginia Telehealth statute (Va. Code 38.2-3418.16) expanded coverage mandates and prescribing permissions statewide [9].

Addyi remains in the Sprout REMS program, requiring prescriber enrollment, but REMS enrollment can be completed online and does not require an in-person visit. Patients must receive counseling about the alcohol interaction risk, which telehealth platforms document through structured informed consent workflows.

Several national telehealth platforms with Virginia licensure, including those specializing in women's sexual health, prescribe flibanserin. Most require an asynchronous questionnaire or a brief synchronous video consultation. Typical telehealth platform fees range from $0 to $75 for the initial consultation in Virginia, though medication costs are separate.

Telehealth prescriptions for Addyi can be sent to any Virginia-licensed retail pharmacy or, where a 503A partnership exists, to a compounding pharmacy. The prescribing clinician must hold a valid Virginia medical or advanced practice license and must be enrolled in the REMS.

A 2021 retrospective analysis in Telemedicine and e-Health (N=412) found that telehealth-initiated HSDD treatment had a medication adherence rate of 74 percent at 12 weeks, comparable to in-person prescribing rates reported in office-based cohorts [10].

Clinical Efficacy: What the Trials Show

Understanding Addyi's cost is useful only in the context of its demonstrated benefit. Two key phase 3 trials, BEGONIA (N=1,378) and VIOLET (N=1,267), form the core of the FDA approval package. In BEGONIA, patients receiving flibanserin 100 mg nightly reported a mean increase of 0.5 satisfying sexual events per 28 days over placebo at 24 weeks, alongside a statistically significant reduction in distress on the Female Sexual Distress Scale-Revised (FSDS-R, P<0.001) [3].

The VIOLET trial, published in the Journal of Sexual Medicine, replicated these findings, showing a similar SSE improvement and FSDS-R distress reduction in a comparable premenopausal population [11]. Both trials excluded women with depression being treated with SSRIs, which is a practical prescribing consideration given flibanserin's serotonergic mechanism.

The North American Menopause Society (NAMS) 2022 Position Statement on sexual health notes that flibanserin "has demonstrated efficacy for HSDD in premenopausal women" and recommends it as an option when psychosocial and relationship factors have been addressed [12]. NAMS further states that "treatment decisions should incorporate patient preference, comorbidities, and access considerations," directly acknowledging that cost and insurance barriers are clinically relevant.

A Cochrane systematic review of pharmacological treatments for HSDD (2019) found that flibanserin produced a small but statistically significant improvement in SSEs compared with placebo (standardized mean difference 0.27 to 95% CI 0.18 to 0.36) and noted that the clinical significance of this effect size should be discussed with individual patients [13].

The FDA label specifies that Addyi should be discontinued after 8 weeks if the patient does not report a meaningful subjective improvement, which has budgetary implications: patients who respond quickly can commit to ongoing therapy, while non-responders can stop, limiting the cost exposure [1].

Side Effects That Affect Adherence and Cost Planning

Flibanserin's side effect profile is relevant to cost planning because adverse effects are the leading driver of early discontinuation, which affects how long a patient continues paying for the drug. In the BEGONIA trial, 8.2 percent of participants discontinued due to adverse events versus 4.0 percent in the placebo arm [3].

Common adverse effects include:

• Dizziness (11.4 percent in BEGONIA versus 2.2 percent placebo).
• Somnolence (11.3 percent versus 3.0 percent placebo).
• Nausea (10.4 percent versus 3.8 percent placebo).
• Fatigue (9.2 percent versus 5.6 percent placebo).

The alcohol interaction is the most serious safety concern. Combining flibanserin with alcohol causes additive CNS depression and hypotension. The REMS program addresses this with mandatory patient counseling [1]. Patients who drink alcohol regularly should discuss this interaction explicitly with their prescriber before initiating therapy, as it may affect the risk-benefit calculation.

CYP3A4 inhibitors, including fluconazole, erythromycin, grapefruit juice in large quantities, and many HIV protease inhibitors, can increase flibanserin plasma concentrations substantially. The FDA label contraindicates co-administration with moderate to strong CYP3A4 inhibitors [1]. Virginia prescribers conducting medication reconciliation via telehealth should specifically screen for these agents [7].

How Virginia Compares to Neighboring States

Virginia's Medicaid coverage with PA represents a more accessible posture than some neighboring states, which require step therapy (failing a non-pharmacological intervention first before coverage is granted). Maryland Medicaid requires step therapy documentation before approving Addyi. West Virginia Medicaid does not list Addyi on its preferred drug list as of the last published formulary update, meaning non-preferred coverage applies with higher PA burden [14].

North Carolina Medicaid covers Addyi with PA under similar criteria to Virginia. Washington D.C., while technically not a state, covers Addyi under DC Medicaid with PA for residents of the district, relevant to Northern Virginia telehealth patients who may see DC-licensed providers [15].

Virginia's 503A compounding environment is also more permissive than some states, as the Virginia Board of Pharmacy does not add restrictions beyond federal DQSA requirements for non-sterile compounds like flibanserin tablets.

Practical Steps to Access Addyi in Virginia in 2026

Getting Addyi in Virginia requires navigating prescribing, REMS enrollment, insurance verification, and possibly PA. The sequence below reflects current 2026 pathways.

First, confirm you meet the clinical criteria: premenopausal, diagnosed with HSDD by DSM-5 criteria (persistent low sexual desire causing personal distress), and have addressed any contributing factors including relationship issues, thyroid dysfunction, or medication-induced low libido (SSRIs, hormonal contraceptives, antihypertensives).

Second, identify a prescriber enrolled in the Sprout REMS. Any Virginia-licensed MD, DO, NP, or PA with prescribing authority can enroll. Telehealth platforms typically handle REMS enrollment internally.

Third, check your insurance formulary. Call your plan's pharmacy benefits line or check the online formulary tool using Addyi's NDC. Ask specifically about PA requirements and what tier the drug sits on.

Fourth, apply for the Sprout savings card before filling the prescription if you have commercial insurance. The card is activated at the pharmacy point of sale.

Fifth, if cost remains a barrier, ask your prescriber to write for compounded flibanserin 100 mg oral tablets from a Virginia-licensed 503A pharmacy, with documented clinical rationale for the compounded formulation.

A 2023 survey of HSDD patients conducted by the International Society for the Study of Women's Sexual Health (ISSWSH) found that 41 percent of women who received a flibanserin prescription never filled it, with cost cited as the primary barrier in 63 percent of those cases [16]. Proactive cost counseling at the point of prescribing reduces this gap.

Monitoring and Follow-Up Costs in Virginia

Beyond the monthly drug cost, patients should budget for follow-up care. ISSWSH and NAMS both recommend a follow-up assessment at 4 to 8 weeks to evaluate response using a validated instrument such as the FSFI (Female Sexual Function Index) or the FSDS-R [12]. A telehealth follow-up visit in Virginia typically costs $0 to $50 with insurance or $49 to $99 cash pay for a 15-minute synchronous visit.

If the prescriber is an OB-GYN or women's health NP, the follow-up may be billed as an office E/M visit, which most Virginia commercial plans cover at standard specialist cost-sharing. Virginia Medicaid reimburses OB-GYN follow-up visits at the standard DMAS fee schedule rate.

No laboratory monitoring is required by the FDA label for flibanserin. Prescribers may order thyroid function tests or a comprehensive metabolic panel if contributing causes of low libido have not been fully worked up, but these are not mandatory ongoing costs attributable to flibanserin itself [1].